onc-841
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2024 (NCT06219499)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
SIGLEC10 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06352359 | Phase 1 | Aug 23, 2024 | OncoC4, Inc., University of California, Davis |
| NCT06219499 | Phase 1 | Jun 30, 2024 | OncoC4, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoC4, Inc. | For profit | 2 | 2 | 1 | 2024 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1